EC Number | Application | Comment | Organism |
---|---|---|---|
1.3.1.9 | medicine | targeting enoyl-ACP reductase is an attractive approach for the development of novel antibacterials | Streptococcus pneumoniae |
EC Number | Cloned (Comment) | Organism |
---|---|---|
1.3.1.9 | - |
Streptococcus pneumoniae |
EC Number | Crystallization (Comment) | Organism |
---|---|---|
1.3.1.9 | in complex with 1, hanging drop vapour diffusion method, with 0.1 M MES, pH 5.5-7.0, 0.1 M NH4Cl, 0.2 M CaCl2, 8-15% 2-methyl-2,4-pentanediol , 8-15% polyethyleneglycol 1000, and 5 mM dithiothreitol | Streptococcus pneumoniae |
1.3.1.9 | the crystal structure of enoyl-acyl carrier protein reductase is determined at 1.7 A, in complex with a phenylimidazole derivative inhibitor at 2.3 A | Streptococcus pneumoniae |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
1.3.1.9 | AG205 | - |
Streptococcus pneumoniae | |
1.3.1.9 | methyl 2-[[(1H-benzimidazol-2-ylmethyl)carbamoyl]amino]-1,3-benzothiazole-6-carboxylate | AG205 | Streptococcus pneumoniae | |
1.3.1.9 | NADH | - |
Streptococcus pneumoniae | |
1.3.1.9 | sodium (4-[2-[([[5-(pyridin-2-ylsulfanyl)-1,3-thiazol-2-yl]carbamoyl]amino)methyl]-1H-imidazol-4-yl]phenoxy)acetate | competitive inhibitor with respect to NADH and uncompetitive inhibitor with respect to crotonyl-CoA | Streptococcus pneumoniae |
EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
1.3.1.9 | 0.007 | - |
crotonyl-CoA | - |
Streptococcus pneumoniae | |
1.3.1.9 | 0.067 | - |
NADH | - |
Streptococcus pneumoniae |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
1.3.1.9 | additional information | Streptococcus pneumoniae | FabK catalyzes the reduction of enoyl-ACPs with the concomitant oxidation of NADH | ? | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
1.3.1.9 | Streptococcus pneumoniae | - |
- |
- |
1.3.1.9 | Streptococcus pneumoniae | Q8DR17 | - |
- |
EC Number | Purification (Comment) | Organism |
---|---|---|
1.3.1.9 | - |
Streptococcus pneumoniae |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
1.3.1.9 | crotonyl-CoA + NAD+ | inhibition assay | Streptococcus pneumoniae | ? | - |
? | |
1.3.1.9 | crotonyl-CoA + NADH + H+ | - |
Streptococcus pneumoniae | butyryl-CoA + NAD+ | - |
? | |
1.3.1.9 | additional information | FabK catalyzes the reduction of enoyl-ACPs with the concomitant oxidation of NADH | Streptococcus pneumoniae | ? | - |
? |
EC Number | Subunits | Comment | Organism |
---|---|---|---|
1.3.1.9 | dimer | x-ray crystallography | Streptococcus pneumoniae |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
1.3.1.9 | enoyl-acyl carrier protein reductase | - |
Streptococcus pneumoniae |
1.3.1.9 | FabK | - |
Streptococcus pneumoniae |
EC Number | pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|---|
1.3.1.9 | 7 | - |
inhibition assay | Streptococcus pneumoniae |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
1.3.1.9 | FMN | - |
Streptococcus pneumoniae | |
1.3.1.9 | NADH | - |
Streptococcus pneumoniae |
EC Number | Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|---|
1.3.1.9 | 0.000011 | - |
sodium (4-[2-[([[5-(pyridin-2-ylsulfanyl)-1,3-thiazol-2-yl]carbamoyl]amino)methyl]-1H-imidazol-4-yl]phenoxy)acetate | - |
Streptococcus pneumoniae | |
1.3.1.9 | 0.000029 | - |
NADH | - |
Streptococcus pneumoniae |